一种基于含有克洛法滨的适体-PROTAC的混合治疗策略，用于增强癌症治疗。
A cocktail therapeutic strategy based on clofarabine-containing aptamer-PROTAC for enhanced cancer therapy.
发表日期：2023 Sep 08
作者：
Zhenzhen Chen, Mohan Chen, Ran Liu, Huanhuan Fan, Jingjing Zhang
来源：
BIOMEDICINE & PHARMACOTHERAPY
摘要：
通过在母本Aptamer-PROTAC内引入治疗性核苷酸类似物尾部，设计并评估了一种PROTAC鸡尾酒系统（ApTCs-3X）。ApTCs-3X具有改善的核酸酶耐受性，并能有效降解靶蛋白，具有亚细胞定位偏好。该鸡尾酒疗法能够提高治疗效果，适用于推进PROTAC在联合疗法中的应用。
By introducing a therapeutic nucleoside analogue tail to the parent Aptamer-PROTACs, a PROTAC-cocktail system (ApTCs-3X) was designed and evaluated. ApTCs-3X exhibited improved nuclease resistance and efficiently degraded target protein with subcellular localization preference. This cocktail therapy results in enhanced therapeutic outcomes, making it suitable for advancing PROTAC in combination therapy.